|
53
|
186
|
4m6lA |
Crystal structure of human dihydrofolate reductase (dhfr) bound to nadp+ and 5,10-dideazatetrahydrofolic acid |
|
49
|
168
|
4m7vA |
Dihydrofolate reductase from enterococcus faecalis complexed with nadp(h)and rab-propyl |
|
143
|
608
|
4ky4A |
Crystal structure of non-classical ts inhibitor 2 in complex with toxoplasma gondii ts-dhfr |
|
43
|
157
|
4laeX |
Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines |
|
43
|
159
|
4kneA |
Crystal structure of dihydrofolate reductase from mycobacterium tuberculosis in complex with cycloguanil |
|
50
|
159
|
4kjkA |
Room temperature wt dhfr |
|
43
|
157
|
4lagX |
Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines |
|
42
|
160
|
4kl9A |
Crystal structure of dihydrofolate reductase from mycobacterium tuberculosis in the space group c2 |
|
51
|
186
|
4kd7A |
Human dihydrofolate reductase complexed with nadph and 5-{3-[3-methoxy-5(pyridine-4-yl)phenyl]prop-1-yn-1-yl}-6-ethyl-pyrimidine-2,4-diamine |
|
158
|
563
|
4kyaA |
Crystal structure of non-classical ts inhibitor 3 in complex with toxoplasma gondii ts-dhfr |
|
46
|
161
|
4km0A |
Crystal structure of dihydrofolate reductase from mycobacterium tuberculosis in complex with pyrimethamine |
|
41
|
157
|
4lahX |
Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines |
|
43
|
161
|
4klxA |
Crystal structure of dihydrofolate reductase from mycobacterium tuberculosis in an open conformation. |
|
54
|
186
|
4kebA |
Human dihydrofolate reductase complexed with nadph and 5-{3-[3-methoxy-5-(isoquin-5-yl)phenyl]but-1-yn-1-yl}6-ethylpyrimidine-2,4-diamine |
|
55
|
186
|
4kakA |
Crystal structure of human dihydrofolate reductase complexed with nadph and 6-ethyl-5-[(3s)-3-[3-methoxy-5-(pyridine-4-yl)phenyl]but-1-yn-1-yl]pyrimidine-2,4-diamine (ucp1006) |
|
158
|
519
|
4ky8A |
Crystal structure of ts-dhfr from cryptosporidium hominis in complex with nadph, methotrexate, fdump and 4-((2-amino-6-methyl-4-oxo-4,7-dihydro-3h-pyrrolo[2,3-d]pyrimidin-5-yl)thio)-2-chlorophenyl)-l-glutamic acid |
|
50
|
159
|
4kjjA |
Cryogenic wt dhfr |
|
53
|
186
|
4kbnA |
Human dihydrofolate reductase complexed with nadph and 5-{3-[3-(3,5-pyrimidine)]-phenyl-prop-1-yn-1-yl}-6-ethyl-pyrimidine-2,4diamine |
|
50
|
160
|
4kjlA |
Room temperature n23pps148a dhfr |
|
42
|
159
|
4km2A |
Crystal structure of dihydrofolate reductase from mycobacterium tuberculosis in an open conformation in complex with trimethoprim |
|
53
|
186
|
4kfjA |
Human dihydrofolate reductase complexed with nadph and 5-{3-[3-methoxy-5-(isoquin-5-yl)phenyl]prop-1-yn-1-yl}6-ethylprimidine-2,4-diamine |
|
43
|
157
|
4lekX |
Structure-based design of new dihydrofolate reductase antibacterial agents: 7-(benzimidazol-1-yl)-2,4-diaminoquinazolines |
|
56
|
206
|
4ixfX |
Pcdhfr-269 f69n variant |
|
47
|
159
|
4i1nA |
R104a-ca1697 nanobody binding to the binary dhfr.folate complex |
|
57
|
206
|
4ixgX |
Pcdhfr-268-k37s-n69f variant |
|
46
|
159
|
4i13A |
Nanobody ca1697 binding to the dhfr.folate binary complex |
|
60
|
206
|
4ixeD |
Pcdhfr-nadph-270 |
|
58
|
192
|
4hofA |
Candida albicans dihydrofolate reductase complexed with nadph and 5-[3-(2-methoxy-4-phenylphenyl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine (ucp111h) |
|
59
|
192
|
4hoeA |
Candida albicans dihydrofolate reductase complexed with nadph and 5-[3-(2,5-dimethoxy-4-phenylphenyl)but-1-yn-1-yl]-6-methylpyrimidine-2,4-diamine (ucp111e) |
|
46
|
189
|
4h96A |
Candida albicans dihydrofolate reductase complexed with nadph and 5-{3-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methoxyphenyl]prop-1-yn-1-yl}-6-ethylpyrimidine-2,4-diamine (ucp1018) |
|
51
|
189
|
4h95A |
Candida albicans dihydrofolate reductase complexed with nadph and 6-ethyl-5-{3-[3-methoxy-5-(pyridin-4-yl)phenyl]but-1-yn-1-yl}pyrimidine-2,4-diamine (ucp1006) |
|
58
|
224
|
4h98A |
Candida glabrata dihydrofolate reductase complexed with nadph and 5-{3-[3-(2,3-dihydro-1,4-benzodioxin-6-yl)-5-methoxyphenyl]prop-1-yn-1-yl}-6-ethylpyrimidine-2,4-diamine (ucp1018) |
|
54
|
190
|
4h97A |
Candida albicans dihydrofolate reductase complexed with nadph and 5-{3-[3-methoxy-5-(4-methylphenyl)phenyl]but-1-yn-1-yl}-6-methylpyrimidine-2,4-diamine (ucp111d4m) |
|
56
|
204
|
4g8zX |
Pcdhfr k37s/f69n double mutant tmp nadph ternary complex |
|
45
|
162
|
4gh8A |
Crystal structure of a 'humanized' e. coli dihydrofolate reductase |
|
55
|
186
|
4g95A |
Hdhfr-oag binary complex |
|
43
|
163
|
4fggA |
S. aureus dihydrofolate reductase co-crystallized with propyl-dap isobutenyl-dihydrophthalazine inhibitor |
|
41
|
159
|
4fhbA |
Enhancing dhfr catalysis by binding of an allosteric regulator nanobody (nb179) |
|
44
|
159
|
3r33A |
Evidence for dynamic motion in proteins as a mechanism for ligand dissociation |
|
40
|
163
|
4fghA |
S. aureus dihydrofolate reductase co-crystallized with ethyl-dap isobutenyl-dihydrophthalazine inhibitor |
|
45
|
159
|
3qyoA |
Sensitivity of receptor internal motions to ligand binding affinity and kinetic off-rate |
|
58
|
219
|
3qfxA |
Trypanosoma brucei dihydrofolate reductase pyrimethamine complex |
|
59
|
192
|
3qlrA |
Candida albicans dihydrofolate reductase complexed with nadph and 6-methyl-5-[(3r)-3-(3,4,5-trimethoxyphenyl)pent-1-yn-1-yl]pyrimidine-2,4-diamine (ucp112a) |
|
177
|
608
|
3qgtA |
Crystal structure of wild-type pfdhfr-ts complexed with nadph, dump and pyrimethamine |
|
56
|
192
|
3qlsA |
Candida albicans dihydrofolate reductase complexed with nadph and 6-methyl-5-[3-methyl-3-(3,4,5-trimethoxyphenyl)but-1-yn-1-yl]pyrimidine-2,4-diamine (ucp115a) |
|
43
|
160
|
3ql0A |
Crystal structure of n23pp/s148a mutant of e. coli dihydrofolate reductase |
|
173
|
608
|
3qg2A |
Plasmodium falciparum dhfr-ts qradruple mutant (n51i+c59r+s108n+i164l, v1/s) pyrimethamine complex |
|
46
|
159
|
3ql3A |
Re-refined coordinates for pdb entry 1rx2 |
|
53
|
190
|
3qlwA |
Candida albicans dihydrofolate reductase complexed with nadph and 5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine (ucp120b) |
|
46
|
159
|
3qylA |
Sensitivity of receptor internal motions to ligand binding affinity and kinetic off-rate |
